LONG-TERM TREATMENT USING A FIXED-DOSE COMBINATION OF PERINDOPRIL AND AMPLODIPINE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ARTERIAL HYPERTENSION

Download full text PDF
Issue: 
8
Year: 
2015

Professor A. Strutynsky, MD; V. Trishina, Candidate of Medical Sciences; Yu. Golubev, Candidate of Medical Sciences; G. Golubeva, Candidate of Medical Sciences; E. Beketova; E. Gorbacheva N.I. Pirogov Russian National Research Medical University

The efficiency of long-term (12-month) treatment with a fixed-dose combination of perindopril and amlodipine (Prestans, Servier) was studied in 68 patients with chronic obstructive pulmonary disease and arterial hypertension. This treatment was shown not only to produce a stable antihypertensive effect, to decrease left ventricular mass, and to considerably improve left ventricular diastolic function, but also to significantly lower pulmonary artery systolic pressure and to reduce the sizes of the right ventricle, the echographic signs of its systolic and diastolic dysfunction, the clinical and spirographic signs of bronchial obstructive syndrome, and the level of proinflammatory cytokines (tumor necrosis factor-α and interleukin-6).

Keywords: 
Prestans
chronic obstructive pulmonary disease
arterial hypertension
proinflammatory cytokines



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Avdeev. S.N. Hronicheskaja obstruktivnaja bolezn' legkih kak sistemnoe zabolevanie // Pul'monologija. – 2007; 2: 104–16.
  2. Sin D., Man S. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease // Circulation. – 2003; 107: 1514–9.
  3. Huiart L., Ernst P., Suissa S. Cardiovascular morbidity and mortality in COPD. // Chest. – 2005; 128: 2640–6.
  4. Adasheva T.V., Zadionchenko V.S., Matsievich M.V. i dr. Arterial'naja gipertonija i HOBL – ratsional'nyj vybor terapii // RMZh. – 2006; 14 (10): 795–800.
  5. Adasheva T.V., Fedorova I.V., Zadionchenko V.S. i dr. Antigipertenzivnaja terapija u bol'nyh HOBL: preimuschestva antagonistov kal'tsija. // Ratsional'naja farmakoterapija v kardiologii. – 2008; 5: 39–45.
  6. Zadionchenko V.S., Adasheva T.V., Li V.V. i dr. Arterial'naja giperten zija i HOBL — problemy vybora terapii // Lechaschij vrach. – 2012; 7: 77–82.
  7. Mason R., Mak I., Trumbore M. Antioxidant properties of calcium antagonists related to membrane biophysical interactions // Am. J. Cardiol. – 1999; 84:16–22.
  8. Berkels R., Taubert D., Bartels H. et al. Amlodipine increases endothelial nitric oxide by dualmechanismus // Pharmacology. – 2004; 70: 39–45.
  9. Belenkov Ju.N., Mareev V.Ju., Ageev F.T. Ingibitory APF v lechenii serdechno-sosudistyh zabolevanij (Kvinapril i endotelial'naja funktsija) / M.: 2002; 86 s.
  10. Bakaev R.G., Strutynskij A.V., Sivtseva A.I. Effektivnost' dlitel'noj terapii bronholitikami, fenspiridom i perindoprilom bol'nyh HOBL i HLS // Kardiovask. ter. i profilakt. – 2010; 5: 66–73.
  11. Bertoli L. Effects of captopril on hemodynamics and blood gases in chronic obstructive lung disease with pulmonary hypertension // Respiration. – 1996; 4: 251–6.
  12. Sever P., Dahlof B., Poulter N. et al. for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. // Lancet. – 2005; 366: 895–906.
  13. Bahl V. et al. Management of hypertension with the fixed combination of perindipril and amlodipine in daily clinical practice. Results from the STRONG prospective, Observational, Multicenter Study // Cardiovasc. Drug. – 2009; 9: 136–42.
  14. Hatala R., Bachanova K., Sidlo R. SYMBIO: Results of a longitudinal study of optimized blood pressurelowering therapy with fixed combination perindopril/amlodipine. ESH 2010 // J. Hypertension. – 2010; 28: 5–169.
  15. Karpov Ju.A., Deev A.D. ot imeni vrachej – uchastnikov programmy «PRORYV». Nekontroliruemaja arterial'naja gipertonija – novye vozmozh-nosti v reshenii problemy povyshenija effektivnosti lechenija // Kardiologija. – 2012; 2: 29–35.
  16. Kobalava Zh.D., Kotovskaja Ju.V., Luk'janova E.A. Kombinirovannaja terapija AG s ispol'zovaniem fiksirovannoj kombinatsii perindoprila i amlodipina v real'noj klinicheskoj praktike: organizatsija i osnovnye rezul'taty programmy KONSTANTA // Kardiologija. – 2013; 6: 25–34.
  17. Nikitin A.V., Gosteva E.V., Bulueva H.A. i dr. Opyt primenenija Prestansa u bol'nyh IBS v sochetanii s somaticheskoj patologiej. // Vestnik novyh meditsinskih tehnologij. – 2013; 2 (20): 181–5.
  18. Rojtberg G.E., Strutynskij A.V. Vnutrennie bolezni. Sistema organov dyhanija / M.: Medpress-inform, 2014; 625 s.
  19. Strutynskij A.V., Glazunov A.B., Moshkova N.K. i dr. Osobennosti remodelirovanija pravyh i levyh otdelov serdtsa u bol'nyh legochnym serd-tsem i AG // Serdechnaja nedostatochnost'. – 2007; 6: 284–8.
  20. Bryant D., Becker L., Richardson J. et al. Cardiac failure in transgenic mice with myocardial exppression of tumor necrosis factor-a. // Circulation. – 1998; 97: 1375–81.
  21. Vasjuk Ju.A., Dudarenko O.P., Juschuk E.N. i dr. «Tsitokinovaja» model' patogeneza HSN i vozmozhnosti novogo terapevticheskogo podhoda v lechenii dekompensirovannyh bol'nyh // Ratsional'naja farmakoterapija v kardiolo-gii. – 2006; 4: 63–70.
  22. Kobalava Zh.D., Kotovskaja Ju.V. Arterial'naja gipertenzija: novoe v diagnostike i lechenii / M.: 2006; 368 s.
  23. Mukatova A.M. i dr. Novye vozmozhnosti v lechenii patsientov s AG v uslovijah statsionara. Rezul'taty issledovanija KONTROL' // Meditsina. – 2012; 7: 34–6.
  24. Avdeev S.N., Tsareva N.A., Chuchalin A.G. Lechenie legochnoj gipertenzii pri hronicheskoj obstruktivnoj bolezni legkih // Serdechnaja nedostatoch-nost'. – 2002; 3 (13):144–8.